DACAB: Ticagrelor and Aspirin Improve Vein Graft Patency

According to this Chinese study, dual antiplatelet therapy with ticagrelor and aspirin improves vein graft patency a year after surgery without increasing the risk for major bleeding.

DACAB: el ticagrelor y la aspirina mejoran la permeabilidad de los puentes venosos

 

Treatment with the P2Y12 inhibitor ticagrelor in combination with aspirin has been widely accepted for patients with acute coronary syndrome undergoing angioplasty. However, there were no related data regarding surgical revascularization.


Read also: Ticagrelor Versus Clopidogrel in Symptomatic Peripheral Vascular Disease”.


This new information is of great interest, since 25% of all vein grafts are occluded after a year and about half of them are occluded after 10 years.

 

The DACAB study, presented at the American Heart Association (AHA) 2017 Scientific Sessions, enrolled 500 patients who underwent myocardial revascularization surgery and treatment with ticagrelor, aspirin, or both. All patients were started on their therapy within 24 hours after the surgery.

 

Vein graft patency at one year was superior in patients in the dual antiplatelet therapy group compared with those receiving aspirin alone (88.7% vs. 76.5%; p = 0.006).


Read also: The End of Aspirin for Anticoagulated Patients Undergoing PCI”.


The rate of combined events was highest in the aspirin monotherapy arm (5.4%) compared with the ticagrelor alone arm (2.4%), and the combination therapy group (1.8%).

 

Due to certain study design limitations, many experts said that these results are interesting but preliminary.

 

Original title: Efficacy and Safety of a Dual Ticagrelor Plus Aspirin Antiplatelet Strategy After Coronary Artery Bypass Grafting: The DACAB Randomized Clinical Trial.

Reference: Zhao Q. American Heart Association 2017 Scientific Sessions. 12 de noviembre del 2017.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

STEACS and the Use of Bivalirudin vs. Heparin: In Search of BRIGHT-4 Outcomes

Various studies and registries have previously shown the impact of post-percutaneous coronary intervention (PCI) complications on the survival of patients with ST-segment elevation acute...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

Ultrathin vs Thin-Strut Stents in PCI Patients at High Bleeding Risk

Several in vivo studies have shown that ultrathin stents present lower thrombogenic risk vs. thin-strut stents, which reflects in lower rates of target lesion...

Should We Withdraw Anticoagulation Before TAVR?

Approximately one-third of patients undergoing transcatheter aortic valve replacement (TAVR) have atrial fibrillation and are on oral anticoagulant (OAC) therapy. This creates a complex...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....